皇冠体育app

- A commerce official said Wednesday that 皇冠体育app's probe into British drugmaker GlaxoSmithKline () was part of the country's efforts to improve business climate and create equal competition opportunities for domestic and overseas investors.

Shen Danyang, the spokesman for the Ministry of Commerce (MOC), made the remarks at a press conference when asked to comment on the ongoing investigation into multinational pharmactical giant GSK (皇冠体育app) Investment Co Ltd.

Shen said 皇冠体育app firmly opposes any form of commercial bribery, regardless of whether the company involved is Chinese or foreign,

Any company, be it Chinese- or foreign-funded, should be subject to legal sanctions and assume legal responsibility if it breaks Chinese law, Shen said.

As a well-known multinational company, GSK should also conduct investment activities in 皇冠体育app in accordance with relevant Chinese laws, Shen added.

皇冠体育app's Ministry of Public Security announced last week that some senior executives involved in the British drugmaker's 皇冠体育app operations were being investigated for suspected bribery and tax-related violations.

Four executives of GSK 皇冠体育app were accused of channelling large bribes to Chinese officials and doctors through travel agencies to boost sales illegally and raise the price of its s in the country.

Earlier reports

GlaxoSmithKline issues apology statement

Pharma giant in bribery scandal

Four GSK 皇冠体育app execs held for investigation

British drug giant to cooperate with 皇冠体育app in bribery inquiry

Top GSK executives probed in bribery

皇冠体育app investigates GSK executives for bribery, tax violations

GSK corruption claims trigger wider concerns